Gulmira Alipova

Gulmira Alipova

Auto-generated profile, based on publicly available information

Gulmira Alipova


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 March 2021 in International Professional Journal "Medicine"
Verified
Journal Article
Closed access
SCShymkent Turkestan Regional Cardiology Center
Shymkent Turkestan Regional Cardiology Center
GAGulmira Alipova
Gulmira Alipova
ABAnna Bazarova
Anna Bazarova
NBNazira Bazarova
Nazira Bazarova
K3Karaganda Polyclinic No 3
Karaganda Polyclinic No 3
MTMeyramgul Tundybaeva
Meyramgul Tundybaeva
The article presents the results of the DAPA-HF study - evaluating the efficacy of dapagliflozin, used at a dose of 10 mg once a day, in addition to the standard treatment for patients with chronic heart failure with reduced left ventricular ejection fraction, compared to placebo. An analysis of current clinical recommendations related to this issue was carried out, the results of recent clinical studies and metaanalyses conducted were highlighted. Based on the results of the study, the need is postulated to optimize drug therapy of this category to patients with persistent symptoms of heart failure, despite standard therapy, with the addition of dapagliflozin to reduce the risk of cardiovascular death and hospitalizations for heart failure, improve the course of the disease. Keywords: chronic heart failure, dapagliflozin, low ejection fraction, effects of type 2 sodium-glucose co transporter inhibitors, diabetes mellitus.